International Cholangiocarcinoma Research Network (ICRN)

The International Cholangiocarcinoma Research Network (ICRN) concept was introduced by members of the CCF’s Medical, Clinical Science, and Basic Science Advisory Boards during the Cholangiocarcinoma Foundation Annual Meeting in Salt Lake City, Utah in February 2015.

The ICRN is a global collaboration of research groups from renowned institutions that are working in concert to improve knowledge about cholangiocarcinoma etiology, prevention, early detection, treatment and prognosis. The network is comprised of highly talented individuals from a spectrum of disciplines, perspectives, and research methods who share the passion to make significant scientific advances that improve outcomes for patients with cholangiocarcinoma.

ICRN-Final

The goal of ICRN is to accelerate the clinical translation of scientific discoveries to impact the lives of patients with cholangiocarcinoma.

Goals

Engages global expertise towards finding a cure for cholangiocarcinoma

  • Identifies specific areas of expertise within the ICRN institutions and engages key stakeholders
  • Brings together institutions to support the identification, design, and implementation of multi-center clinical research initiatives
  • Creates allied partnerships with industry, academia, regulatory, and patient-centered organizations
  • Attracts and supports the training of the next generation of cholangiocarcinoma investigators and incentivizes senior researchers to focus in the field

Facilitates multi-center basic, translational, and clinical research to ensure rapid translation from bench to bedside

  • Identifies critical research gaps and establishes priority areas in cholangiocarcinoma
  • Avoids unnecessary duplication and reduces regulatory burden involved in network studies
  • Enables ethical research and collaboration between academia and study sponsors
  • Consolidates state-of-the-art information and shares network resources (biobanks, databases, preclinical models and repositories)

Outcomes

  • Accelerates scientific and medical progress on an international level
  • Expedites delivery of innovative care and treatments to patients
  • Increases access to clinical trials for patients with cholangiocarcinoma
  • Nurtures dedicated cholangiocarcinoma researchers

Create an internet-based, secure, iMedidata Rave Registry for the study of cholangiocarcinoma

  • Develop a centralized repository of clinical information of patients having or at risk for CC
  • Pool de-identified data from multiple sites in uniform format for collaborative research studies
  • Use HIPAA-compliant database maintained by study team at Mayo Clinic, under an IRB approved protocol

Increase access to clinical trials for patients with cholangiocarcinoma

  • Establish a clinical trials network focused on collaboration
  • Vet clinical trials to expedite development of novel and effective therapies
  • Build molecular databases with clinical annotation so as to define ‘targetable’ disease subsets
  • Create online searchable resources for patients looking for innovative research options

International Cholangiocarcinoma Research Network (ICRN) Map

ICRN Steering Committee


Dr. Milind Javle

Milind Javle, MD

UT MD Anderson Cancer Center
ICRN Chair

Mitesh Borad, MD

Mayo Clinic, Arizona
ICRN Co-Chair


Ghassan Abou-Alfa, MD

Memorial Sloan Kettering Cancer Center

a-elkhoueiry

Anthony El-Khoueiry, MD

USC Norris Comprehensive Cancer Center

renukaiyer

Renuka Iyer, MD

Roswell Park Cancer Center

mac-kkelly

Katie Kelley, MD

University of California, San Francisco Cancer Center

lroberts

Lewis Roberts, MB, ChB, PhD

Mayo Clinic, Minnesota

Juan Valle, MB, ChB, MSc, FRCP

University of Manchester /The Christie NHS Foundation Trust


Andrew Zhu, MD

Massachusetts General Hospital Cancer Center


Pin It on Pinterest